#USA #Los Angeles #Nervonik #Medical Device #Peripheral Nerve

Nervonik Welcomes New Leaders to Enhance Nerve Stimulation Technology Development

Nervonik, Inc., a pioneering medical technology firm focused on advancing a next-generation peripheral nerve stimulation platform for chronic pain relief, has announced a significant expansion of its leadership team. The incorporation of seasoned executives aims to bolster the company's capabilities as it transitions toward the critical stages of clinical and commercial launch.

On July 13, 2026, Nervonik revealed that they had appointed three notable figures from the medical technology sector: Rob DiTota, Dan Brounstein, and Patrick Martin. These individuals bring extensive experience in various aspects of the medical field, including commercialization, clinical strategy, regulatory execution, and market development, which will be instrumental in Nervonik achieving its operational milestones.

Key Appointments

• - Rob DiTota has been appointed as the Chief Commercial Officer. With over 30 years of healthcare experience, including 25 years specifically in the MedTech arena, DiTota has a proven track record. Previously, he served as the Divisional Vice President of Commercial at Abbott Neuromodulation, where he played a pivotal role in shaping U.S. commercial strategies and promoting physician engagement with neuromodulation therapies.

• - Dan Brounstein joins as the Chief Strategy and Marketing Officer, contributing more than three decades of medical device experience. Brounstein previously held the position of Chief Strategy Officer at Saluda Medical, where he was integral to the launch of the Evoke spinal cord stimulation system for chronic pain management. His expertise in taking medical technologies from conception to market positions him as an invaluable asset for Nervonik's strategic goals.

• - Patrick Martin, who takes on the role of Vice President of Clinical Affairs, brings a rich background in clinical and regulatory affairs exceeding 30 years. His previous experience at Nalu Medical as Vice President of Clinical Affairs has equipped him with the necessary skills to navigate the clinical landscape effectively. Martin’s role will be crucial as Nervonik progresses towards its commercial ambitions.

In welcoming the new leaders, Aydin Babakhani, Ph.D., Founder and CEO of Nervonik expressed, "Nervonik is entering an important stage of growth, and the addition of Rob, Dan, and Patrick significantly strengthens our ability to execute. They each bring hard-earned experience from the front lines of neuromodulation and medical device commercialization, which will no doubt help us accelerate our development and bring our health technologies to those who need them most."

Nervonik's Vision

Nervonik is committed to developing a groundbreaking peripheral nerve stimulation platform designed to overcome the limitations traditionally associated with neuromodulation treatments. The company’s innovative technology seeks to combine a compact implant with adaptive power communication and advanced biosensing capabilities. This sophisticated integration aims to deliver personalized therapies, enhancing treatment efficacy and patient comfort.

This leadership expansion follows a robust period of progress for Nervonik, underscoring the company’s commitment to innovation in chronic pain management solutions. With the impending 510(k) submission and plans for commercial launch on the horizon, the newly formed leadership team is poised to propel Nervonik towards achieving its ambitious goals in the medical device industry.

About Nervonik

Nervonik, Inc. is headquartered in Los Angeles, California. The company focuses on pioneering neuromodulation technologies designed to harness stimulation, sensing, and artificial intelligence for precise therapies targeting chronic pain and other neurological conditions. The team’s expertise and the recent strategic leadership additions signify a promising future for the company as it forges ahead in the medical technology landscape.